Brief: Codiak Provides Platform-Validating Clinical Update And Data From Phase 1 Trials Of Exosting And Exoil-12
30/06/2022 11:34
June 30 (Reuters) - Codiak BioSciences, Inc. CDAK.O :
* CODIAK PROVIDES PLATFORM-VALIDATING CLINICAL UPDATE AND
DATA
FROM PHASE 1 TRIALS OF EXOSTING™ AND EXOIL-12™
* CODIAK BIOSCIENCES - EXOSTING & EXOIL-12 DEMONSTRATED
FAVORABLE
SAFETY & TOLERABILITY PROFILE
Source text for Eikon: ID:nGNX71Rzyv
Further company coverage: CDAK.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Codiak BioSciences,.
See all newsBrief: Codiak Biosciences Notice From Listing Qualifications Department Of Nasdaq Trading Of Co's Common Stock To Be Suspended At Opening Of Business On April 5
U.S. STOCKS ON THE MOVE-Energy firms, crypto stocks, Walt Disney
U.S. STOCKS ON THE MOVE-Cyclerion, banks, Jounce Therapeutics
U.S. STOCKS ON THE MOVE-Tesla, BrainStorm, Pinterest
Codiak BioSciences down after co files for Chapter 11 bankruptcy